Lighting the Way to a Cure

  • Financials
  • Patient Library
  • Blog
  • Calendar
en English
en Englishes Spanishfr Frenchde Germanit Italiannl Dutchru Russianzh-CN Chinese (Simplified)ja Japanesehi Hindiiw Hebrewpt Portuguese
FSHD Header Logo
mobile-logo
  • Who We Are
        • About Us
          • History
          • Mission
          • Our Team
        • Our Impact
          • Therapeutic Accelerator
          • Education
          • Advocacy
          • Our Partners
        • Extraordinary Measures
          • 2021 Donor Impact Report
          • 2020 Donor Impact Report
  • Understanding FSHD
        • What is FSHD
          • Symptoms
          • Diagnosis
          • Early-onset FSHD
          • Genetic Testing
        • Living with FSHD
          • Newly Diagnosed?
          • Finding Care
          • Symptom Management
          • Patient Library
        • FSHD University
          • Physical Health
          • Wellness
          • Research
  • Get Involved
        • Support Us
          • Ways to Give
          • Become a Torch Bearer
          • Raise Awareness
          • Volunteer
          • Fundraise
        • Advance Research
          • Patient Involvement
          • Join the True Cost of FSHD Study
          • Clinical Trials
          • Donate tissue
        • Connect
          • Find Your Local Chapter
          • Join the Community
          • World FSHD Alliance
          • Online Communities
        • Events
          • Walk & Roll to Cure FSHD
          • Events Calendar
          • FSHD 360 Regional Conferences
          • FSHD Connect Conference
  • Research
        • For Patients & Families
          • Advance Research
          • True Cost of FSHD Study
          • TestFSHD genetic testing
          • Clinical Trials
        • For Researchers
          • Apply for a Grant
          • Grants We Have Funded
          • Resources
          • Int’l Research Congress
        • For Clinicians
          • FSHD Masterclass
          • ICD-10
        • For Industry
          • Therapeutic Accelerator
          • Clinical Trial Research Network
          • Drug Development Pipeline
          • Voice of the Patient Report
  • News
    • Media Library
    • Blog
      • Living with FSHD
        • Health and Medicine
        • PT and Exercise
        • Tips and Tricks
        • Mental Health
      • FSHD Society News
      • FSHD Research
      • Fundraising & Events
      • Media & PR
    • FSHD Society Radio
    • The FSHD Advocate
  • JOIN US
  • DONATE

Arrowhead Pharmaceuticals announces FSHD drug candidate

Home / FSHD Research / Arrowhead Pharmaceuticals announces FSHD drug candidate

Posted on: Apr 15, 2021

Arrowhead Pharmaceuticals, Inc., a Pasadena, California, company, today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate. Using the company’s proprietary Targeted RNAi Molecule (TRIMTM) platform, ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD). Pending abstract acceptance, Arrowhead intends to present preclinical data on ARO-DUX4 at the 28th Annual FSHD Society International Research Congress being held virtually on June 24-25, 2021. Arrowhead is currently conducting IND/CTA enabling toxicology studies and intends to file for regulatory clearance in the third quarter of 2021 to begin clinical studies of ARO-DUX4.

Join our Research Contact Registry

“In our various animal models, ARO-DUX4 reduced DUX4 expression by greater than 70%, prevented body weight loss associated with tamoxifen-induced DUX4 expression, and prevented loss of muscle function,” said Chris Anzalone, Ph.D., president and chief executive officer at Arrowhead. (In these studies, tamoxifen, a drug used to treat tumors, is used as an artificial switch to turn on the DUX4 gene in mice that have been genetically engineered to do so. Switching on DUX4 in the mice leads to muscle degeneration and weakness, similar to that seen in the human disease. Normally, tamoxifen does not affect DUX4 expression, so individuals with FSHD should not be concerned that taking tamoxifen might trigger the progression of symptoms.)

Read the full press release here.

Share

Filed Under: FSHD Research

Comments

  1. Adriana says

    April 16, 2021 at 9:12 am

    Me interesa ya que padezco FDH,al igual que mis hermanos.

    Reply
  2. Jim says

    April 19, 2021 at 12:26 pm

    This sounds like the most targeted potential treatment we’ve seen announced.

    Reply
  3. Salvatore Sofia says

    May 3, 2021 at 8:27 pm

    This sounds very promising!! So as a person that has FSHD how do we get involved in any clinical trials, etc. Please provide any such contact information!!! Thank You!!!!

    Reply
  4. Javier says

    May 6, 2021 at 1:53 am

    As potential affected, I’d like to take part of this clinical trials or wherever…
    Congratulations for your job, our solution smells it’s near…

    Reply
  5. Richard Poskin says

    May 6, 2021 at 8:08 am

    I would be interested in pursuing this for my adult son with FSHD. What are the next steps? He does not live on the west coast, so geography may be an issue.

    Reply
    • jkinoshita says

      May 6, 2021 at 8:30 am

      Please make sure your son is signed up too, because clinical trial alerts are usually targeted to the geographic region where a prospective volunteer is living. Here’s the link: https://www.fshdsociety.org/for-patients-families/join-fshd-research-contact-registry/

      Reply
  6. Ray sawa says

    June 8, 2021 at 11:59 am

    How does one get involved with these trials

    Reply
    • jkinoshita says

      June 21, 2021 at 1:05 pm

      Clinical trials are typically restricted to individuals who meet the inclusion criteria for the trial and are in the geographic area of a trial site, or who are willing to commit to traveling to participate in the trial. To make sure you are notified about opportunities to volunteer for a trial, be sure to join our Research Contact Registry:
      https://www.fshdsociety.org/for-patients-families/join-fshd-research-contact-registry/

      Reply
  7. Lesley says

    June 17, 2021 at 12:02 pm

    This is really interesting, but I’m sorry to say I got confused. Are the mouse given tamoxifen only to simulate or provoke symptoms similar to FSHD in humans? And then does this mean that people with FSHD would not need to take tamoxifen when given the TRIM therapeutic? Thanks for any clarification!

    Reply
  8. Fletcher Barton says

    June 17, 2021 at 1:01 pm

    Let me suggest the last sentence be rewritten as “Normally, tamoxifen does not affect DUX4 expression, so individuals with FSHD who take tamoxifen should not be concerned it might trigger the progression of symptoms.” Without revision, the sentence seems to imply tamoxifen is given as part of treatment.

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

SEARCH

Categories

  • FSHD Research
  • FSHD Society News
    • Extraordinary Measures
  • Fundraising & Events
  • General
  • Living with FSHD
    • Health and Medicine
    • Mental Health
    • PT and Exercise
    • Tips and Tricks
  • Media & PR

Sign up for Email Alerts

Stay up to date with the latest FSHD news and updates from FSHD Society.

CONNECT WITH US

Proud Member World FSHD Alliance (1)
Footer-Logo-min

Donation Address:

Department 960, P O Box 4106
Woburn, MA 01888    U.S.A.

General Mailing Address:

75 North Main Street, Suite 1073
Randolph, MA 02368 U.S.A.

(781) 301-6060

  • DONATE
  • Donate
  • Join Us
  • Inclusivity & Equity
  • Privacy Policy
  • Contact Us
  • Glossary Of Scientific Terms
Digital Marketing by